JP2018520091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520091A5 JP2018520091A5 JP2017557287A JP2017557287A JP2018520091A5 JP 2018520091 A5 JP2018520091 A5 JP 2018520091A5 JP 2017557287 A JP2017557287 A JP 2017557287A JP 2017557287 A JP2017557287 A JP 2017557287A JP 2018520091 A5 JP2018520091 A5 JP 2018520091A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- activatable antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022022910A JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156835P | 2015-05-04 | 2015-05-04 | |
| US62/156,835 | 2015-05-04 | ||
| US201562220805P | 2015-09-18 | 2015-09-18 | |
| US62/220,805 | 2015-09-18 | ||
| PCT/US2016/030785 WO2016179285A1 (en) | 2015-05-04 | 2016-05-04 | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022910A Division JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520091A JP2018520091A (ja) | 2018-07-26 |
| JP2018520091A5 true JP2018520091A5 (enExample) | 2019-06-20 |
| JP7028648B2 JP7028648B2 (ja) | 2022-03-02 |
Family
ID=55967468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557287A Expired - Fee Related JP7028648B2 (ja) | 2015-05-04 | 2016-05-04 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| JP2022022910A Withdrawn JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022910A Withdrawn JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10745481B2 (enExample) |
| EP (2) | EP3708585A1 (enExample) |
| JP (2) | JP7028648B2 (enExample) |
| KR (1) | KR20180010203A (enExample) |
| CN (2) | CN107849133B (enExample) |
| AU (1) | AU2016257929B2 (enExample) |
| BR (1) | BR112017023872A2 (enExample) |
| CA (1) | CA2984948A1 (enExample) |
| DK (1) | DK3292150T3 (enExample) |
| EA (1) | EA201792414A1 (enExample) |
| ES (1) | ES2796698T3 (enExample) |
| HR (1) | HRP20200721T1 (enExample) |
| HU (1) | HUE049866T2 (enExample) |
| IL (2) | IL292798A (enExample) |
| MX (2) | MX388350B (enExample) |
| PL (1) | PL3292150T3 (enExample) |
| PT (1) | PT3292150T (enExample) |
| RS (1) | RS60222B1 (enExample) |
| SG (2) | SG10201913767VA (enExample) |
| WO (1) | WO2016179285A1 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11089959B2 (en) | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US9782075B2 (en) | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| RU2727836C2 (ru) * | 2013-07-25 | 2020-07-24 | Сайтомкс Терапьютикс, Инк. | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения |
| MX379106B (es) | 2013-09-25 | 2025-03-11 | Cytomx Therapeutics Inc | Substratos de metaloproteinasas de matriz y otras porciones escindibles y métodos para usar los mismos. |
| IL317045A (en) * | 2014-01-31 | 2025-01-01 | Cytomx Therapeutics Inc | Polypeptide substrates activating tryptase and U-plasminogen and other cleavable groups, compositions containing them and uses thereof |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN107849133B (zh) | 2015-05-04 | 2022-08-23 | 西托姆克斯治疗公司 | 抗cd166抗体、可活化抗cd166抗体及其使用方法 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| US12060654B2 (en) | 2016-11-28 | 2024-08-13 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| JP7001615B2 (ja) | 2016-11-28 | 2022-02-03 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| EA201991353A1 (ru) | 2016-12-09 | 2019-11-29 | Двухвалентные антитела, маскированные спирализованными спиралями | |
| KR20200027971A (ko) * | 2017-07-14 | 2020-03-13 | 싸이톰스 테라퓨틱스, 인크. | 항-cd166 항체 및 이의 용도 |
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| KR20200040819A (ko) | 2017-08-16 | 2020-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| CA3074112A1 (en) * | 2017-08-30 | 2019-03-07 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
| JP2020534811A (ja) * | 2017-09-08 | 2020-12-03 | マベリック セラピューティクス， インコーポレイテッドＭａｖｅｒｉｃｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｆｃ領域を含有する条件的に活性化された結合部分 |
| IL317013A (en) | 2017-09-08 | 2025-01-01 | Takeda Pharmaceuticals Co | Binding proteins are activated under limited conditions |
| JP7482630B2 (ja) | 2017-11-28 | 2024-05-14 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| SG11202004627WA (en) | 2017-11-28 | 2020-06-29 | Chugai Pharmaceutical Co Ltd | Ligand-binding molecule having adjustable ligand-binding activity |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| US20220023439A1 (en) * | 2018-11-02 | 2022-01-27 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
| CN113271956B (zh) | 2018-12-06 | 2025-04-29 | 西托姆克斯治疗公司 | 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法 |
| US20220089752A1 (en) * | 2019-01-14 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND USES THEREOF |
| US20220233705A1 (en) * | 2019-02-26 | 2022-07-28 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| JP2022527449A (ja) | 2019-03-21 | 2022-06-02 | イミュノジェン・インコーポレーテッド | 細胞結合剤－薬物複合体の調製方法 |
| KR102212149B1 (ko) * | 2019-03-28 | 2021-02-04 | 부산대학교 산학협력단 | 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도 |
| EP4316524A3 (en) | 2019-04-26 | 2024-04-24 | ImmunoGen, Inc. | Camptothecin derivatives |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| US20220226514A1 (en) * | 2019-05-17 | 2022-07-21 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| US20220324975A1 (en) | 2019-06-05 | 2022-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody cleavage site binding molecule |
| WO2020251878A1 (en) | 2019-06-11 | 2020-12-17 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| CN114650844A (zh) * | 2019-09-23 | 2022-06-21 | 西托姆克斯治疗公司 | 抗cd47抗体、可活化抗cd47抗体及其使用方法 |
| CA3155981A1 (en) | 2019-11-14 | 2021-05-20 | William Winston | Activatable cytokine polypeptides and methods of use thereof |
| IL296634A (en) | 2020-04-09 | 2022-11-01 | Cytomx Therapeutics Inc | Preparations containing activatable antibodies |
| CA3185040A1 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CA3199133A1 (en) * | 2020-11-16 | 2022-05-19 | Feng Lin | Anti-cd6 antibody conjugates for treating t-cell and b-cell mediated disorders, and t-cell and b-cell cancers |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| EP4416178A1 (en) | 2021-10-15 | 2024-08-21 | CytomX Therapeutics, Inc. | Activatable polypeptide complex |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250011422A1 (en) * | 2021-11-12 | 2025-01-09 | University Of Florida Research Foundation, Incorporated | Siglec-6 antibodies, derivative compounds and related uses |
| CN114621348B (zh) * | 2022-01-24 | 2023-09-22 | 深圳市乐土生物医药有限公司 | 一种多肽及其抗磷脂酰肌醇蛋白聚糖3抗体 |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| WO2023192606A2 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| US20250215110A1 (en) | 2022-04-01 | 2025-07-03 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| CA3251998A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
| EP4554625A1 (en) | 2022-07-12 | 2025-05-21 | CytomX Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
| JP2025525879A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性基質及びその使用方法 |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| EP4565261A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120958015A (zh) | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025047993A1 (en) * | 2023-08-28 | 2025-03-06 | Pharosgen Co., Ltd. | Anti-doppel antibody drug conjugates |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
| US5998172A (en) | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
| WO1999011287A1 (en) | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| JP2005524399A (ja) | 2002-05-03 | 2005-08-18 | レイヴェン バイオテクノロジーズ， インコーポレイテッド | Ａｌｃａｍおよびａｌｃａｍ調節因子 |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| EP2213684A3 (en) | 2003-12-22 | 2011-05-18 | Glaxo Group Limited | Nogo-a antibodies for the treatment of Alzheimer disease |
| AU2006285850A1 (en) | 2005-08-29 | 2007-03-08 | Japan Science And Technology Agency | Antibody produced using ostrich and method for production thereof |
| EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF |
| US7582441B1 (en) | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
| WO2007063825A1 (ja) | 2005-11-29 | 2007-06-07 | Japan Science And Technology Agency | Cd166に対するモノクローナル抗体およびその産生方法 |
| US20090220529A1 (en) | 2006-03-10 | 2009-09-03 | Diatos, S.A. | Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker |
| WO2008007648A1 (fr) | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
| GB0705775D0 (en) | 2007-03-26 | 2007-05-02 | Affitech As | Product |
| JP2009055899A (ja) | 2007-08-07 | 2009-03-19 | Igaku Seibutsugaku Kenkyusho:Kk | Ａｄｃｃ活性を増強させた抗体及びその製造方法 |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| EP2192922A4 (en) | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| CA2714296A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| MX2010011808A (es) | 2008-04-30 | 2011-03-04 | Immunogen Inc | Conjugados potentes y enlazadores hidrofilicos. |
| US8846870B2 (en) | 2008-12-22 | 2014-09-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-HS6ST2 antibodies and uses thereof |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP5812418B2 (ja) | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
| CA2816681A1 (en) | 2010-11-03 | 2012-05-10 | Immunogen, Inc. | Cytotoxic agents comprising new ansamitocin derivatives |
| US20140199233A1 (en) | 2011-05-11 | 2014-07-17 | The Regents Of The University Of California | Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor |
| CN104520324A (zh) * | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| WO2013163631A2 (en) | 2012-04-27 | 2013-10-31 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| CN105008918A (zh) | 2013-01-04 | 2015-10-28 | 西托姆克斯治疗公司 | 用于检测生物系统中的蛋白酶活性的组合物和方法 |
| EP3566750A3 (en) | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| JP6660294B2 (ja) | 2013-06-04 | 2020-03-11 | シトムクス セラピューティクス，インコーポレイティド | 活性化可能抗体を結合するための組成物及び方法 |
| RU2727836C2 (ru) * | 2013-07-25 | 2020-07-24 | Сайтомкс Терапьютикс, Инк. | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения |
| CN107849133B (zh) | 2015-05-04 | 2022-08-23 | 西托姆克斯治疗公司 | 抗cd166抗体、可活化抗cd166抗体及其使用方法 |
| WO2017015227A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating cd166-expressing cancer |
| JP7534070B2 (ja) | 2015-11-04 | 2024-08-14 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| WO2017218750A1 (en) | 2016-06-15 | 2017-12-21 | The Cleveland Clinic Foundation | Novel anti-cd6 antibodies for treating t-cell mediated conditions |
| JP6183523B2 (ja) | 2016-09-14 | 2017-08-23 | 株式会社アンセイ | 車両用開閉体の開閉装置及び車両用開閉体の開閉装置用リンク機構 |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| US11376332B2 (en) | 2016-10-15 | 2022-07-05 | Baylor College Of Medicine | Platform for enhanced targeted delivery |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| KR20200027971A (ko) | 2017-07-14 | 2020-03-13 | 싸이톰스 테라퓨틱스, 인크. | 항-cd166 항체 및 이의 용도 |
| CA3074112A1 (en) | 2017-08-30 | 2019-03-07 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
| US20220023439A1 (en) | 2018-11-02 | 2022-01-27 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
| US20220233705A1 (en) | 2019-02-26 | 2022-07-28 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
-
2016
- 2016-05-04 CN CN201680038634.3A patent/CN107849133B/zh not_active Expired - Fee Related
- 2016-05-04 IL IL292798A patent/IL292798A/en unknown
- 2016-05-04 RS RS20200511A patent/RS60222B1/sr unknown
- 2016-05-04 EA EA201792414A patent/EA201792414A1/ru unknown
- 2016-05-04 SG SG10201913767VA patent/SG10201913767VA/en unknown
- 2016-05-04 US US15/146,603 patent/US10745481B2/en active Active
- 2016-05-04 BR BR112017023872A patent/BR112017023872A2/pt not_active IP Right Cessation
- 2016-05-04 PL PL16722502T patent/PL3292150T3/pl unknown
- 2016-05-04 SG SG10202110908WA patent/SG10202110908WA/en unknown
- 2016-05-04 EP EP20155149.6A patent/EP3708585A1/en not_active Withdrawn
- 2016-05-04 AU AU2016257929A patent/AU2016257929B2/en not_active Expired - Fee Related
- 2016-05-04 HR HRP20200721TT patent/HRP20200721T1/hr unknown
- 2016-05-04 KR KR1020177034835A patent/KR20180010203A/ko not_active Abandoned
- 2016-05-04 ES ES16722502T patent/ES2796698T3/es active Active
- 2016-05-04 HU HUE16722502A patent/HUE049866T2/hu unknown
- 2016-05-04 PT PT167225028T patent/PT3292150T/pt unknown
- 2016-05-04 WO PCT/US2016/030785 patent/WO2016179285A1/en not_active Ceased
- 2016-05-04 DK DK16722502.8T patent/DK3292150T3/da active
- 2016-05-04 CN CN202210950237.0A patent/CN115340607A/zh active Pending
- 2016-05-04 CA CA2984948A patent/CA2984948A1/en active Pending
- 2016-05-04 MX MX2017014136A patent/MX388350B/es unknown
- 2016-05-04 JP JP2017557287A patent/JP7028648B2/ja not_active Expired - Fee Related
- 2016-05-04 EP EP16722502.8A patent/EP3292150B1/en active Active
-
2017
- 2017-11-02 IL IL255414A patent/IL255414B/en unknown
- 2017-11-03 MX MX2021014735A patent/MX2021014735A/es unknown
-
2019
- 2019-12-20 US US16/723,809 patent/US11753466B2/en active Active
-
2022
- 2022-02-17 JP JP2022022910A patent/JP2022065115A/ja not_active Withdrawn
-
2023
- 2023-07-18 US US18/354,353 patent/US20240076374A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520091A5 (enExample) | ||
| JP2018520991A5 (enExample) | ||
| JP2018520092A5 (enExample) | ||
| EP3292149B1 (en) | Activatable anti-cd71 antibodies, and methods of use thereof | |
| Carter et al. | Antibody-drug conjugates for cancer therapy | |
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| TWI872065B (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| JP2017522871A5 (enExample) | ||
| JP2018516539A (ja) | 抗ｃ−Ｍｅｔ抗体および抗ｃ−Ｍｅｔ抗体−細胞毒性薬物複合体ならびにそれらの医薬用途 | |
| CN108136015A (zh) | 抗dll3抗体药物缀合物以及使用方法 | |
| CN105288644A (zh) | 抗体-药物缀合物 | |
| Zhang et al. | Novel development strategies and challenges for anti-Her2 antibody-drug conjugates | |
| CN112020519A (zh) | 抗her2双互补位抗体-药物偶联物及使用方法 | |
| CN111295201A (zh) | 抗egfr抗体药物结合物（adc）和其用途 | |
| Bera et al. | Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability | |
| Jin et al. | An anti-EGFR× cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations | |
| Hui et al. | An innovative site-specific anti-HER2 antibody-drug conjugate with high homogeneity and improved therapeutic index | |
| CN112175082B (zh) | 抗叶酸受体α抗体、其缀合物及其用途 | |
| CN111278462A (zh) | 抗egfr抗体药物结合物(adc)和其用途 | |
| JP7130243B2 (ja) | 二重特異性抗体を用いた抗体薬物複合体プラットホーム | |
| JPWO2021251459A5 (enExample) | ||
| Zhong et al. | A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| AU2018285523A1 (en) | Antibody drug conjugates that bind LGR5 |